Logo Image
|Articles|April 4, 2016

It’s a Revolution: Real World Data & Patient Health Outcomes

Author(s)DIA

Explore combining clinical trial data with real world data collected in real clinical practice: Clinical trials are conducted in controlled circumstances, but real clinical practice is not. Not every diagnosis is correct. Not all prescribed drugs are taken by the patient according to the prescription. Some patients have more than one disease, or take more than one medicine. The reality of treating and curing patients is much more complex and messy than the orderly world of clinical trials.

Read more here.

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
Read more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more